Revive Therapeutics Announces Proposed Shares for Debt Settlement

Rhea-AI Summary

Revive Therapeutics (OTCQB:RVVTF) announced a proposed debt settlement under which it intends to issue up to 1,221,516 common shares at a deemed price of $0.05 per share. The issuance would settle an aggregate of $61,061 in outstanding trade payables owed to two arm's length creditors.

The settlement shares will be issued in accordance with Canadian Securities Exchange policies and will be subject to a statutory hold period of four months and one day. Completion is conditional on receiving necessary regulatory approvals, including CSE acceptance, and is expected to close no earlier than five business days from the announcement date.

Positive

• Proposed elimination of $61,061 in trade payables via share issuance
• Use of up to 1,221,516 shares at a fixed deemed price of $0.05
• No cash outlay disclosed for settling the $61,061 payables

Negative

• Potential dilution from issuing up to 1,221,516 new common shares
• Debt settlement remains conditional on regulatory approvals, including CSE acceptance
• Settlement shares subject to a four months and one day statutory hold period

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, announces a proposed debt settlement pursuant to which the Company intends to issue up to 1,221,516 common shares in the capital of the Company (the "Settlement Shares") at a deemed price of $0.05 per Settlement Share to settle an aggregate of $61,061 in outstanding trade payables owing to two arm's length creditors of the Company (the "Debt Settlement").

The Settlement Shares will be issued in accordance with the policies of the Canadian Securities Exchange (the "CSE"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws. Completion of the Debt Settlement remains subject to certain conditions, including receipt of all necessary regulatory approvals, including approval of the CSE.

The Debt Settlement is expected to close no earlier than five business days from the date of this news release and remains subject to CSE acceptance

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1-888-901-0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

SOURCE: Revive Therapeutics Ltd.

View the original press release on ACCESS Newswire

FAQ

What debt is Revive Therapeutics (RVVTF) settling with its August 19, 2026 share issuance plan?

Revive Therapeutics plans to settle $61,061 in outstanding trade payables. According to Revive Therapeutics, the obligations are owed to two arm's length creditors and would be satisfied through issuing common shares instead of cash, subject to regulatory approvals.

How many shares will Revive Therapeutics (RVVTF) issue in the proposed August 2026 debt settlement?

Revive Therapeutics intends to issue up to 1,221,516 common shares. According to Revive Therapeutics, these settlement shares are priced at a deemed value of $0.05 each and will be used to retire specific trade payables, pending required regulatory approvals.

What is the deemed price per share in Revive Therapeutics' August 19, 2026 RVVTF debt settlement?

The deemed price is $0.05 per common share. According to Revive Therapeutics, this price will be applied to up to 1,221,516 settlement shares issued to two arm's length creditors to clear $61,061 of trade payables, subject to Canadian Securities Exchange acceptance.

When is the Revive Therapeutics (RVVTF) debt settlement expected to close?

The debt settlement is expected to close no earlier than five business days from August 19, 2026. According to Revive Therapeutics, completion also depends on receiving all necessary regulatory approvals, including acceptance from the Canadian Securities Exchange.

Are the new RVVTF settlement shares from Revive Therapeutics' August 2026 debt deal freely tradable?

No, the settlement shares will initially be restricted. According to Revive Therapeutics, all shares issued under the debt settlement will be subject to a statutory hold period of four months and one day from the issuance date, under applicable securities laws.

What regulatory approvals are required for Revive Therapeutics' (RVVTF) August 2026 debt settlement?

The transaction requires necessary regulatory approvals, including Canadian Securities Exchange (CSE) approval. According to Revive Therapeutics, completion of the debt settlement remains conditional on CSE acceptance and other required clearances before the proposed share issuance can proceed.